Gandrille S, Alhenc-Gelas M, Gaussem P, Aillaud M F, Dupuy E, Juhan-Vague I, Aiach M
Groupe de Recherche sur la Thrombose, INSERM CJF 91-01, UFR des Sciences pharmaceutiques et biologiques, Paris, France.
Blood. 1993 Jul 1;82(1):159-68.
We describe five families presenting with type II hereditary protein C deficiency characterized by normal antigen and amidolytic activity levels but low anticoagulant activity. All the exons and intron/exon junctions of the protein C gene were studied using a strategy combining amplification by the polymerase chain reaction (PCR), denaturing gradient gel electrophoresis of the amplified fragments, and direct sequencing of fragments displaying altered melting behavior. We detected five novel mutations. Three were located in the C-terminal part of the propeptide encoded by exon III: Arginine (Arg)-5 to tryptophan (Trp), Arg-1 to histidine (His), and Arg-1 to cysteine (Cys) mutations. The two others, located in exon IX, affected Arg 229 and serine (Ser) 252, which were respectively replaced by glutamine (Gln) and asparagine (Asn). DNA studies of the other exons from affected individuals showed no other abnormalities. These novel mutations provide further insight into the importance of the affected amino acids located close to the active site, near Asp 257, one of the three amino acids of the catalytic triad. The low anticoagulant activity of the abnormal protein C indicated that Arg 229 and Ser 252 play a key role during the interaction between protein C and its cofactor protein S, phospholipids, or factors Va and VIIIa. The Arg-1 to Cys mutation led to the dimerization of protein C with another plasmatic component, as evidenced by the presence in the plasma of a high molecular weight form of protein C that disappeared after reduction. No molecular mass abnormalities were observed in heavy and light chains of all other protein C mutants. In the five families explored, 9 (64%) of the 14 subjects bearing the mutations reported thrombotic events. This suggests that the protein C amino acids affected by the mutations are very important for the in vivo expression of the antithrombotic properties of protein C.
我们描述了五个呈现II型遗传性蛋白C缺乏症的家族,其特征为抗原和酰胺水解活性水平正常,但抗凝活性较低。使用聚合酶链反应(PCR)扩增、扩增片段的变性梯度凝胶电泳以及对显示熔解行为改变的片段进行直接测序相结合的策略,研究了蛋白C基因的所有外显子和内含子/外显子接头。我们检测到五个新突变。三个位于外显子III编码的前肽C末端部分:精氨酸(Arg)-5突变为色氨酸(Trp)、Arg-1突变为组氨酸(His)以及Arg-1突变为半胱氨酸(Cys)突变。另外两个位于外显子IX,影响了Arg 229和丝氨酸(Ser)252,它们分别被谷氨酰胺(Gln)和天冬酰胺(Asn)取代。对患病个体其他外显子的DNA研究未显示其他异常。这些新突变进一步揭示了靠近活性位点(靠近催化三联体的三个氨基酸之一的Asp 257)的受影响氨基酸的重要性。异常蛋白C的低抗凝活性表明,Arg 229和Ser 252在蛋白C与其辅因子蛋白S、磷脂或因子Va和VIIIa之间的相互作用中起关键作用。Arg-1突变为Cys的突变导致蛋白C与另一种血浆成分二聚化,血浆中存在的高分子量形式的蛋白C在还原后消失证明了这一点。在所有其他蛋白C突变体的重链和轻链中未观察到分子量异常。在研究的五个家族中,14名携带突变的受试者中有9名(64%)报告了血栓形成事件。这表明受突变影响的蛋白C氨基酸对于蛋白C抗血栓特性的体内表达非常重要。